Source directory
ClinicalTrials.gov
- Glycogen storage disease trial posts its phase 3 results
- Rybrevant Faspro · head and neck cancer · OrigAMI-4 (NCT06385080) began.
- Jemperli · rectal cancer · ClinicalTrials.gov first posted the AZUR-1 study record (NCT05723562).
- Genglycos · glycogen storage disease Ia · The phase 3 study DTX401-CL301 (NCT05139316) began.
- Fayuvi · Sanfilippo syndrome type A · The treatment study (NCT02716246) began.
FDA
- FDA forms a safety council to follow biologics after approval
- Infilbray wins approval for neurological symptoms of type 3 Gaucher disease
- FDA clears Lembaz for infantile-onset Niemann-Pick type C
- Rybrevant Faspro gains a head and neck cancer indication
- FDA grants accelerated approval for Jemperli in a subset of rectal cancers
- Fayuvi gains approval for pediatric Sanfilippo syndrome type A
- Genglycos · glycogen storage disease Ia · FDA granted accelerated approval as an adjunct to nutritional management for patients aged eight and older.
- Fayuvi · Sanfilippo syndrome type A · FDA licensed Fayuvi to treat neurological manifestations of pediatric Sanfilippo syndrome type A in the indicated population.